NCT03194425Unknown不适用
Pelvic Floor EMG Monitoring as Tool to Improve Patient Selection and Outcome - Standardization of Lead Placement for Sacral Neuromodulation.
适应症
干预措施
试验速览
- 阶段
- 不适用
- 入组人数
- 60
- 试验地点
- 2
- 主要终点
- EMG activity of pelvic floor muscles in OAB patients and NOUR patients already on SNM
研究概览
简要总结
Retrospective case-control study.
A substantial number of patients do not respond favourably to sacral neurostimulation (SNS) although clinically, they appear to have the same lower urinary tract dysfunction characteristics as the ones with good responses. This may be due to methodological issues (lead position) or patient selection. The purpose of this study is to improve and standardize lead position, in order to increase the patient response to test stimulation and to SNS treatment, and to decrease adverse events.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Diagnostic
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female aged ≥18 years and competent to provide consent
- •Minimum 3 months of self-reported OAB symptoms or self-reported obstructive LUTS in addition to confirmed non-obstructive urinary retention on UDO
- •Failed, or are not a candidate for more conservative treatment (i.e., pelvic floor training, biofeedback, behavioral modification, oral pharmacotherapy)
- •Willing to discontinue OAB medications for 2 weeks prior to the implant and for the entire study period
- •Able to thoroughly fill in all questionnaires, voiding diaries and office visits for device programming and clinical evaluations before the TLP, 3 weeks after TLP and 6 weeks, 6 months and 1 year after implantation of definitive IPG.
排除标准
- •Current of prior evidence of primary stress incontinence or mixed incontinence where the stress component overrides the urgency component
- •Any neurological condition that may interfere with normal bladder function, including stroke, multiple sclerosis, Parkinson's disease, clinically significant peripheral neuropathy, or spinal cord injury (e.g., paraplegia)
- •Urinary tract mechanical obstruction including but not limited to Benign Prostatic Hyperplasia (BPH)
- •Treatment of bladder or pelvic floor dysfunction with botulinum toxin (Botox ®) or surgery in past 12 months
- •Unable to toilet self and have and maintain good personal hygiene
- •Unable to provide clear, thoughtful responses to questions and questionnaires
- •Urinary tract, bladder or vaginal infection or inflammation
- •Hematuria, and absence of an elaborate diagnostic work-up
- •Severe or uncontrolled diabetes (A1C > 8, documented in the last 3 months) or diabetes with peripheral nerve involvement
- •Allergy to local anesthetic or adhesives
- •Bleeding disorder or on an anticoagulant that cannot be stopped for 3 days before the implant
- •Pregnant, lactating, planning to become pregnant, given birth in the past 12 months, or female of child-bearing potential and not practicing a medically-approved method of birth control
- •Skin lesions or compromised skin at the implant or stimulation site
- •Use of investigational drug or device therapy or participation in any study involving or impacting gynecologic, urinary or renal function within past 4 weeks
- •Passive implants (e.g., prostheses) are allowed, but no implanted metal should be at the Neurostimulator implant site
- •Knowledge of planned MRIs, diathermy, or high output ultrasonic exposure
- •Presence of a documented condition or abnormality that could compromise the safety of the patient
- •Any psychiatric or personality disorder at the discretion of the study physician
- •Interstitial cystitis or bladder pain syndrome as defined by the EAU guidelines
- •Life expectancy of less than 1 year
研究组 & 干预措施
OAB
Experimental
Patients with overactive bladder on sacral neuromodulation.
干预措施: Pelvic floor EMG (Diagnostic Test)
NOUR
Experimental
Patients with non-obstructive urinary retention on sacral neuromodulation.
干预措施: Pelvic floor EMG (Diagnostic Test)
结局指标
主要结局
EMG activity of pelvic floor muscles in OAB patients and NOUR patients already on SNM
时间窗: 1 day
Latency and amplitude of pelvic floor measured by EMG probe
次要结局
未报告次要终点
研究者
Donald Vaganée
Principal Investigator
Universiteit Antwerpen
研究点 (2)
Loading locations...
相似试验
Unknown
不适用
Standardization of Lead Placement for Sacral Neuromodulation Part 2Non Obstructive Urinary RetentionOveractive BladderNCT03199443Universiteit Antwerpen60
已完成
不适用
Pelvic and Hip Morphometry in Piriformis SyndromePiriformis Muscle SyndromeAnthropometryNCT04600024Fatih Sultan Mehmet Training and Research Hospital45
已完成
不适用
Pelvic Muscle Training and Electrostimulation to Treat Weak Pelvic FloorPelvic Floor Muscle WeaknessIncontinence StressMuscle Weakness ConditionEffects ElectricityNCT06419517Azienda Unita Sanitaria Locale di Piacenza50
已完成
不适用
Effect of EMG Biofeedback in Female Patients With Stress Urinary IncontinenceStress Urinary IncontinenceNCT05366426Kirsehir Ahi Evran Universitesi60
已完成
4 期
A Trial of Pelvic Floor Chemodenervation in Patients Undergoing Physical Therapy for High Tone Pelvic Floor DysfunctionPelvic PainPelvic Floor DysfunctionDyspareuniaNCT03199534EvergreenHealth20